ICU Medical : Q1 2026 ICU Medical Earnings Call Presentation 5726
ICUI
Published on 05/07/2026 at 04:43 pm EDT
ICU Medical
Q1 2026 Conference Call Presentation
1
May 7, 2026
Disclosures
Any statement concerning Management's expectation with respect to future results is a forward-looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the statement to be a representation as to future results.
Future results are subject to risks and uncertainties, including the risk factors described in the Company's filings with the Securities and Exchange Commission, which include those in the most recent Form 10-K and subsequent filings. Actual results in the future may differ materially from Management's current expectations.
These forward-looking statements, including statements about tariffs, the timing and resolution of the 2025 Warning Letter received from the FDA, the anticipated benefits and transition/stand-up costs associated with the recently closed joint venture with Otsuka Pharmaceutical Factory America, Inc., inflation levels, interest rates, global public health crises and other geopolitical events, are made based upon our current expectations and we undertake no duty to update information provided in this presentation.
In addition to the financial measures prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP"), this presentation contains certain non-GAAP financial measures, such as Adjusted EBITDA, adjusted diluted earnings per share ("EPS"), and financial measures presented on a constant currency. Our non-GAAP revenue presented on a constant currency basis uses the average exchange rate for revenues from the prior year applied to the current year results.
These non-GAAP financial measures should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Our management believes that the non-GAAP data provides useful supplemental information to management and investors regarding our performance and facilitates a more meaningful comparison of results of operations between current and prior periods.
2025-2026 Adjusted Revenue
In $Millions
2025
Q1
2025
Q2
2025
Q3
2025
Q4
2025
Total
2026
Q1
Consumables
YoY Growth
YoY Organic Growth 1
266
273
285
285
1,109
278
9%
4%
8%
6%
7%
5%
10%
3%
7%
5%
6%
2%
Systems
YoY Growth YoY Organic Growth 1
166
168
174
176
684
180
6%
2%
9%
3%
5%
8%
8%
2%
8%
1%
5%
6%
Vital Care
YoY Growth
YoY Organic Growth 1
167
103
74
75
419
68
10%
-34%
-52%
-59%
-35%
-59%
11%
-4%
-4%
-6%
1%
-14%
Total ICU
599
544
533
536
2,212
526
YoY Growth
8%
-6%
-8%
-14%
-5%
-12%
YoY Organic Growth 1
10%
2%
5%
2%
5%
1%
Vital Care
Critical Care
Anesthesia & Resp
Warming
Pain Kits
IV
Solutions 1
LVP Infusion
Ambulatory
Syringe
Tracheostomy
Vascular Access
Oncology
Infusion Therapy
1 Organic Growth excludes the impact of foreign currency and the IV Solutions joint venture transaction. In calculating Organic Growth, the following IV Solutions revenues were excluded from the comparison periods as follows: Q2 2024 (May and June) - $50m; Q3 2024 - $79m; Q4 2024 - $103m: Q1 2025 - $89m.
Consumables
Infusion Systems
1 Revenue from IV Solutions is included in ICU Medical's consolidated revenue for all periods prior to the
joint venture formation effective May 1, 2025 and excluded for all periods thereafter.
Disclaimer
ICU Medical Inc. published this content on May 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 07, 2026 at 20:38 UTC.